- Home
- ICCC vs PRLD Comparison
ICCC vs PRLD Comparison
Compare ICCC & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCC
- PRLD
- Stock Information
- Founded
- ICCC 1982
- PRLD 2016
- Country
- ICCC United States
- PRLD United States
- Employees
- ICCC N/A
- PRLD N/A
- Industry
- ICCC Biotechnology: Pharmaceutical Preparations
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- ICCC Health Care
- PRLD Health Care
- Exchange
- ICCC Nasdaq
- PRLD Nasdaq
- Market Cap
- ICCC 46.2M
- PRLD 50.1M
- IPO Year
- ICCC 1987
- PRLD 2020
- Fundamental
- Price
- ICCC $6.83
- PRLD $0.93
- Analyst Decision
- ICCC
- PRLD Strong Buy
- Analyst Count
- ICCC 0
- PRLD 2
- Target Price
- ICCC N/A
- PRLD $4.50
- AVG Volume (30 Days)
- ICCC 27.2K
- PRLD 137.5K
- Earning Date
- ICCC 05-14-2025
- PRLD 05-06-2025
- Dividend Yield
- ICCC N/A
- PRLD N/A
- EPS Growth
- ICCC N/A
- PRLD N/A
- EPS
- ICCC N/A
- PRLD N/A
- Revenue
- ICCC $27,302,766.00
- PRLD $7,000,000.00
- Revenue This Year
- ICCC N/A
- PRLD N/A
- Revenue Next Year
- ICCC N/A
- PRLD N/A
- P/E Ratio
- ICCC N/A
- PRLD N/A
- Revenue Growth
- ICCC 28.29
- PRLD N/A
- 52 Week Low
- ICCC $3.34
- PRLD $0.61
- 52 Week High
- ICCC $6.95
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- ICCC 74.94
- PRLD 54.06
- Support Level
- ICCC $6.00
- PRLD $0.86
- Resistance Level
- ICCC $6.95
- PRLD $1.00
- Average True Range (ATR)
- ICCC 0.39
- PRLD 0.09
- MACD
- ICCC 0.12
- PRLD -0.00
- Stochastic Oscillator
- ICCC 94.12
- PRLD 53.58
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.